Cosibelimab-UNLOXCYT Correct Usage and Dosage Guide

Cosibelimab (UNLOXCYT) is a programmed death ligand -1 (PD-L1) blocking antibody that activates the immune system to attack cancer cells by blocking the binding of PD-L1 and PD-1. The drug is indicated for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC), particularly those who are not candidates for curative surgery or radical radiotherapy. In December 2024, cosibelimab was officially approved by the U.S. Food and Drug Administration (FDA) and became an important option for the treatment of cutaneous squamous cell carcinoma.

The recommended dose of cosibelimab is1200 mg administered by intravenous infusion every 3 weeks. Each infusion takes about 60 minutes and needs to be completed by medical staff in a professional medical institution. Treatment should be continued until disease progression or unacceptable toxicity occurs. Patients need to be reviewed regularly to evaluate treatment effects and side effects.

Before using cosibelimab, patients need to be comprehensively evaluated by a professional doctor, including their condition, physical condition and past medical history, to ensure the suitability and safety of the drug. During the infusion process, medical staff need to closely monitor the patient's vital signs, such as blood pressure, heart rate, etc., to promptly detect and deal with possible allergic reactions or other abnormalities. Cosibelimab may cause common adverse reactions such as fatigue, rash, and diarrhea, as well as serious immune-related adverse reactions such as pneumonia and hepatitis. Patients need to pay close attention to their own conditions and communicate with their doctors in time if they feel unwell.

It should be noted that there is currently insufficient data to support the safety of cosibelimab in pregnant and lactating women, and it should be used with caution. This drug has not been clinically tested in people under the age of 18 and is not recommended for use. When elderly patients use cosibelimab, the treatment plan needs to be adjusted according to their physical condition and monitoring must be strengthened.

Cosibelimab-UNLOXCYT provides a new treatment option for patients with cutaneous squamous cell carcinoma, but its use must strictly follow the recommended dosage and usage. Patients should undergo treatment under the guidance of professional doctors and undergo regular check-ups to evaluate efficacy and side effects. Through scientific management and timely intervention, the therapeutic effect of drugs can be maximized while reducing the risk of adverse reactions.

https://ir.checkpointtx.com/news-events/press-releases/detail/127/checkpoint-therapeutics-announces-fda-approval-of